Axel Heidenreich
Axel Heidenreich is an expert in Urology at University Hospital Cologne (Germany). As of October 2026, ScienceLeadR ranks Axel Heidenreich in the top 1% of experts worldwide for Testicular Neoplasms, Testicular Diseases and Urogenital Neoplasms. Axel Heidenreich has authored 1,271 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 6 of them ongoing. SLR score: 4,632 (community average: 125). How the SLR is computed.
LeadR Profile
Urology
Subspecialties: Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1990 - 2026
Number : 1271
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates. PMID 42925415 — cells, antigens, surface, pharmaceutical preparations, neoplasms, herpesvirus 4, human, prevalence, therapeutics, stomach neoplasms | Langenbecks Arch Surg | 2026 | 0 |
| Post-chemotherapy retroperitoneal lymph node dissection following first-line treatment in patients with advanced pure seminoma of the testis. PMID 42842390 — lymph nodes, testicular neoplasms, multiple chronic conditions, drug therapy, lymph, seminoma, therapeutics, dissection, testis, chemotherapy | J Urol | 2026 | 0 |
| Reducing paralytic ileus after radical cystectomy: The role of advanced haemodynamic monitoring. PMID 42643203 — incidence, cystectomy, ileus, body weight, sex, hemodynamic monitoring | BJUI Compass | 2026 | 0 |
| Guideline recommendations versus real-world management in early-stage testicular cancer: a multicenter survey of contemporary practice. PMID 42571160 — guideline adherence, testicular neoplasms, neoplasms, risk factors, seminoma, therapeutics | Ther Adv Med Oncol | 2026 | 0 |
| [Testicular Germ Cell Tumors and Penile Cancer: Molecular-Based Diagnosis and Treatment]. PMID 42532107 — cells, urology, penile neoplasms, neoplasms, biomarkers, germ cells, diagnosis, therapeutics, alphapapillomavirus, human papillomavirus viruses | Aktuelle Urol | 2026 | 0 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Minimally invasive ICG guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care NCT07699640 — injections, cells, orchiectomy, minimally invasive surgical procedures, safety, lymph nodes, testicular neoplasms, neoplasms, sentinel lymph node, biopsy, lymph, robotic surgical procedures, germ cells, therapeutics, sentinel lymph node biopsy, indocyanine green, dissection | N/A | Not yet recruiting | 2027 |
| A Phase 3 Randomized Open label Multicenter Study Evaluating the Efficacy and Safety of TAR 210 Erdafitinib Intravesical Delivery System Versus Investigator s Choice of Intravesical Chemotherapy in Participants with High risk Non muscle invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette Gu rin (BCG) 2024-519493-39-00 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, bacillus, drug therapy, chemotherapy, non-muscle invasive bladder neoplasms | Phase 3 | Recruiting | 2025 |
| Dato DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la mUC 2024-516906-47-00 — therapeutics, carboplatin, carcinoma | Phase 2/Phase 3 | Recruiting | 2025 |
| Treatment combination of Durvalumab Tremelimumab Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin 2023-507342-84-00 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, cystectomy, therapeutics | Phase 3 | Active not recruiting | 2021 |
| A Phase 3 Randomized Open label Multi center Study Evaluating the Efficacy and Safety of TAR 200 Versus Investigator s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette Gu rin (BCG) and Recurred with High risk Non Muscle Invasive Bladder Cancer (HR NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy 2023-507685-10-00 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, multiple chronic conditions, bacillus, drug therapy, cystectomy, chemotherapy, non-muscle invasive bladder neoplasms | Phase 3 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map